Supporting and advancing your research

Cincinnati Children’s is committed to investing and supporting basic, translational and clinical research. Innovation Ventures is particularly focused on advancing commercially viable research. 

The Takeda and Cincinnati Children’s Research Collaboration is a milestone-driven funding program focused on designing and translating early research to therapeutics. Started in 2015 as a broad research collaboration for rare diseases between Shire and Cincinnati Children’s, the program builds upon Takeda’s patient-centric approach and world-class translational capabilities in therapeutics. Takeda acquired Shire plc in January 2019.

The goal of this collaboration is to accelerate therapies, by combining Takeda’s development and commercialization capabilities with Cincinnati Children’s research expertise. The research collaboration will provide funding and laboratory research support to advance translational research toward the commercial market. Funding will be commensurate with each project's research design and scope of work, as approved by Takeda. Following completion of the funded research, Takeda will have an exclusive option to enter into a license agreement, including intellectual property.

BridgeBio Pharma LLC and Cincinnati Children's Hospital Medical Center entered into a research collaboration in 2018 with the purpose of identifying and developing genetic disease therapies. This partnership combines BridgeBio's strengths in therapeutic development for diseases of high unmet need with Cincinnati Children's world-class researchers and clinicians. Under the terms of the agreement, BridgeBio will have the opportunity to sponsor and collaboratively develop selected research programs. The agreement represents a flexible model that facilitates accelerated genetic disease research.

Launched in 2012 and facilitated by the Innovation Ventures, the Innovation Fund was created to accelerate marketable projects-helping discoveries reach their full potential. As an internal funding mechanism, the Fund provides up to $100,000 in total direct funding, for one year, to an innovator, or innovation team at Cincinnati Children's. Projects needing proof-of-concept/early stage bridge funding, with a goal of attracting outside investment, are the perfect fit for this internal funding mechanism.

Grant funds are to be used to enable product development and commercialization. Examples include the development of prototypes; human clinical data; pre-clinical data; drug delivery platform/systems; large animal studies; algorithmic diagnostics, as opposed to single biomarker associations; or other advanced pre-commercial research. Applications must fit into one of the following categories: Biologic, Cell & Tissue Therapies; Diagnostics; Medical Devices; Digital Health & Care Delivery; or Small Molecule Therapies.

Check out our 2019 Innovation Fund & TVSF Recipients!

Adare Pharmaceuticals is an expert in providing enhanced medicines that create new possibilities for improved patient health. In 2015, Cincinnati Children's and Adare partnered to establish the Adare Drug Optimization and Repurposing Innovation Fund. The Adare Innovation Fund is a focused opportunity and additional funding stream of the broader Cincinnati Children's Innovation Fund program. 

Applicants with Innovation Fund proposals that repurpose a currently marketed product or known drug for a new indication are eligible. Adare is interested in proposals that either optimize or repurpose a known drug for a new indication. Specifically, Adare is interested in studying known therapeutics that could benefit from improved efficacy, improved adverse event/tolerability profiles, improved pharmacokinetic/pharmacodynamic relationships or be developed for an entirely new purpose. Therapeutics must be available for optimizing or repurposing with no more than 5 years of patent exclusivity remaining. Following completion of the funded research program, Adare will have an exclusive option to enter into a licensing agreement for these projects/intellectual property. Adare offers up to $200,000 in funding over two, one-year installments. 

Note: Year 2 funding is contingent upon the successful completion of milestones.

Please contact Ginny Van Horne for additional information.

Cincinnati Children's has two pediatric medical device funds and collaborations. Each effort is designed to develop commercially viable, pediatric specific, medical devices. The structure of each program is different, but all have the same intention of starting pediatric medical device companies in SW Ohio. Below is a brief description of each fund:

  • The Ben-Gurion Cincinnati Children’s Collaborative (BG3C) is a collaborative between Ben-Gurion University of the Negev in Israel and Cincinnati Children's. The collaboration addresses the lack of medical devices designed specifically for children, identifying projects that need to be funded beyond design and development and combining the medical expertise of physicians at Cincinnati Children's with the extensive technical and engineering capabilities of faculty at BGU. The goal is to improve health outcomes by ensuring device design is customized to meet the unique physiological differences and medical needs of children. The collaboration identifies and funds up to three projects each year that meet a medical need and have a strong pathway to commercialization. Each project receives up to $100,000 in funds.
  • University of Dayton – Cincinnati Children's has partnered with the University of Dayton School of Engineering Innovation Center to develop a pathway for creating pediatric medical devices that meet an unmet medical need. Each project is assigned a team of students and a lead faculty member to move the project through a development pipeline. Since 2013, we have worked on one to two projects per year.

We encourage feedback and suggestions for additional collaborations.

If you would like to be among the first to hear about Innovation Ventures industry collaborations/events and to receive links to RFPs when released, please opt-in to our internal distribution list.